CA-NAV-ALLIANCE
9.10.2019 12:02:06 CEST | Business Wire | Press release
The Networking for Autonomous Vehicles (NAV) Alliance , announced that Marvell (NASDAQ: MRVL) is joining the NAV Alliance as a promoter following the completion of its recent acquisition of Aquantia Corp . The NAV Alliance brings together leading automotive manufacturers and technology providers to create an ecosystem for developing the next generation of in-vehicle network infrastructure. Marvell’s advancements in automotive Ethernet, add valued expertise to the NAV Alliance working groups. The company joins 14 other industry leaders in delivering the future of autonomous vehicles including founding members, Bosch, Continental, NVIDIA, and Volkswagen.
“The NAV Alliance is developing the platforms that will create the future of transportation and we believe that Multi-Gig Ethernet is at its core,” said Will Chu, vice president and general manager of the Automotive Business Unit at Marvell Semiconductor, Inc. “We are excited to work alongside other industry leaders to accelerate the development of the innovations that will drive the automotive industry.”
“Marvell’s broad automotive Ethernet product portfolio, including its recently announced family of high-port count, ultra-low latency secure automotive switches with multi-gigabit routing throughput capabilities complements the depth and breadth of the technologies offered by other alliance members. I am pleased that our membership represents all the components necessary to support the in-vehicle network in future autonomous vehicles,” said Amir Bar-Niv, President of the NAV Alliance.
Marvell is an industry leader in the automotive Ethernet connectivity space and offers several networking components for autonomous driving functions including PHYs, controllers, and switches. The company’s inclusion in the NAV Alliance will enhance the efforts of the NAV Alliance technical working groups. The five NAV Alliance technical working groups are:
- Protocol Encapsulation for Ethernet
- System Controls and Management
- 25G and 50G Automotive Ethernet PHY Specifications
- Physical Layer System & Component Integration
- EMC Requirements and Limits
About Marvell
Marvell first revolutionized the digital storage industry by moving information at speeds never thought possible. Today, that same breakthrough innovation remains at the heart of the company's storage, processing, networking, security and connectivity solutions. With leading intellectual property and deep system-level knowledge, Marvell's semiconductor solutions continue to transform the enterprise, cloud, automotive, industrial, and consumer markets. To learn more, visit: https://www.marvell.com/
Marvell and the M logo are registered trademarks of Marvell and/or its affiliates in the US and/or elsewhere. Other names and brands may be claimed as the property of others.
About NAV Alliance
NAV Alliance was created to provide a platform for the automotive industry to develop the next generation of in-vehicle network infrastructure for autonomous vehicles and facilitate wide deployment of networking technologies and products. The Alliance was founded by leading vehicle manufacturers, technology suppliers and networking players in the automotive market, sharing the goal of developing the ecosystem that is required for next-generation Multi-Gig Automotive Ethernet networks in the vehicle. To become a member of the NAV Alliance visit https://www.nav-alliance.org/
NAV ALLIANCE and NAV are trademarks and certification marks of NAV Alliance, Inc. (or its licensor) in the United States and other countries. Unauthorized use is strictly prohibited.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191009005154/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom